Intercept Pharmaceuticals, Inc. financial data

Industry
Pharmaceutical Preparations
Location
305 Madison Avenue, Morristown, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 6, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 264 % -9.58%
Quick Ratio 3.05 % -27.9%
Debt-to-equity 546 %
Return On Equity -82.2 % +18.5%
Return On Assets -12.7 % -132%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41.8M shares +0.99%
Common Stock, Shares, Outstanding 41.8M shares +0.95%
Entity Public Float 335M USD -39.6%
Common Stock, Value, Issued 42K USD +2.44%
Weighted Average Number of Shares Outstanding, Basic 41.8M shares +21.9%
Weighted Average Number of Shares Outstanding, Diluted 41.8M shares +21.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 318M USD +14.6%
Cost of Revenue 632K USD -27.6%
Research and Development Expense 161M USD -13.6%
Costs and Expenses 379M USD +11.3%
Operating Income (Loss) -62.3M USD +21.3%
Nonoperating Income (Expense) 4.17M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -61.6M USD -130%
Earnings Per Share, Basic -1.48 USD/shares -126%
Earnings Per Share, Diluted -1.48 USD/shares -126%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 103M USD -9.24%
Accounts Receivable, after Allowance for Credit Loss, Current 32.5M USD +24.1%
Inventory, Net 2.65M USD -57.8%
Assets, Current 383M USD -29.7%
Property, Plant and Equipment, Net 822K USD -35.6%
Operating Lease, Right-of-Use Asset 7.76M USD -30.5%
Other Assets, Noncurrent 4.97M USD -7.24%
Assets 393M USD -29.7%
Accounts Payable, Current 10.3M USD -51.8%
Liabilities, Current 90.8M USD -59%
Operating Lease, Liability, Noncurrent 7.2M USD +24.9%
Other Liabilities, Noncurrent 6.62M USD -9.22%
Liabilities 321M USD -28.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -7.2M USD +9.61%
Retained Earnings (Accumulated Deficit) -2.18B USD -2.91%
Stockholders' Equity Attributable to Parent 71.8M USD -33.3%
Liabilities and Equity 393M USD -29.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -51.6M USD -156%
Net Cash Provided by (Used in) Financing Activities -254K USD +20.1%
Net Cash Provided by (Used in) Investing Activities 59.3M USD
Common Stock, Shares Authorized 90M shares 0%
Common Stock, Shares, Issued 41.8M shares +0.95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 7.16M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 104M USD -13.7%
Deferred Tax Assets, Valuation Allowance 418M USD -11%
Deferred Tax Assets, Gross 418M USD -18.6%
Operating Lease, Liability 8.85M USD -32.5%
Depreciation 89K USD -73.9%
Payments to Acquire Property, Plant, and Equipment 7K USD -98.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -60.8M USD -130%
Lessee, Operating Lease, Liability, to be Paid 10.1M USD -29.2%
Property, Plant and Equipment, Gross 2.15M USD -56.8%
Operating Lease, Liability, Current 1.65M USD -77.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.44M USD +13.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.93M USD -19%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.26M USD +7.31%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.9M USD +17.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 889K USD -13.9%
Operating Lease, Payments 1.7M USD -22.7%
Additional Paid in Capital 2.26B USD +1.12%
Interest Expense 11.7M USD -64.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%